Andrea Califano, Dr

Academic Appointments

  • Clyde '56 and Helen Wu Professor of Chemical Biology (in Systems Biology) and Professor of Biomedical Informatics and of Biochemistry and Molecular Biophysics (in the Institute for Cancer Genetics)
  • Professor of Biochemistry and Molecular Biophysics

Current Administrative Positions

  • Chair, Department of Systems Biology
  • Director, JP Sulzberger Columbia Genome Center
  • Co-Leader, Precision Oncology and Systems Biology Program, Herbert Irving Comprehensive Cancer Center
Andrea Califano, Dr

Andrea Califano, Dr., is a pioneer in the field of systems biology and founding chair of the Department of Systems Biology at Columbia University Irving Medical Center. A physicist by training, Dr. Califano has taken innovative, systematic approaches to identify the molecular factors that lead to cancer progression and to the emergence of drug resistance at the single-cell level. Directing the conversation about cancer research away from focusing solely on gene mutations, Dr. Califano examines the complex and tumor-specific molecular interaction networks that determine cancer cell behavior. Using information theoretic approaches, analysis of these networks can precisely pinpoint master regulator proteins that are mechanistically responsible for supporting tumorigenesis and for implementing tumor cell homeostasis. Dr. Califano and his lab have shown that master regulators represent critical drivers and tumor dependencies, despite the fact that they are rarely mutated or differentially expressed, thus establishing them as a bona fide new class of therapeutic targets.

The Califano Systems Biology Lab combines computational and experimental methodologies to reconstruct the regulatory and signaling logic of human cells in genome-wide fashion. In addition, his lab has developed methods for the systematic discovery of small molecule compounds and combinations that can inactivate master regulator proteins in cancer, thus providing novel therapeutic hypotheses that can be validated pre-clinically and clinically. Indeed, several of his findings have been translated into clinical studies, including an innovative N-of-1 study at Columbia in which master regulators are identified and pharmacologically targeted on an individual patient basis in several aggressive malignancies, thus getting a step closer to deliver on the promise of a truly mechanistic implementation of precision medicine. Dr. Califano’s master regulator analyses have led to several discoveries that are being tested in the clinics, including the drug entinostat in a subset of metastatic neuroendocrine tumor patients, the use of combination therapy in HER2+ and inflammatory breast cancer, and additional phase 2 clinical trials in patients with recurrent pancreatic ductal carcinoma and metastatic prostate cancer. His research has been funded by the National Cancer Institute, Lustgarten Foundation, Falconwood Foundation, Hyundai Hope on Wheels, the NET Research Foundation, and the Prostate Cancer Foundation.

Dr. Califano is active nationally and internationally, serving as scientific editor of several peer-reviewed journals and on scientific advisory boards, including the Oregon Health & Science University Knight Cancer Institute, the Koch Institute for Integrative Cancer Research at MIT and MD Anderson Division of Cancer Medicine, among others. In 2015, he cofounded biotech startup DarwinHealth, Inc. and currently serves as its chief scientific advisor. He has received several prestigious awards for his contributions to the field, including an Outstanding Investigator Award from the National Cancer Institute (NCI) in 2015 and the Ruth Leff Siegel Award for pancreatic cancer research in 2019. Dr. Califano also has served as chair or co-chair of many international conferences and meetings including the annual meeting of the American Association for Cancer Research (AACR); the RECOMB-ISCB Conference on Regulatory and Systems Genomics, with DREAM Challenges; Keystone Conferences; and several special conferences of the AACR on genomics and cancer systems biology.

Dr. Califano is the Clyde and Helen Wu Professor of Chemical and Systems Biology in the Departments of Systems Biology, Biochemistry & Molecular Biophysics, Biomedical Informatics, and Medicine, and and the founding chair of the Department of Systems Biology. He serves as director of the JP Sulzberger Columbia Genome Center and co-leader of the Precision Oncology and Systems Biology Program at the Herbert Irving Comprehensive Cancer Institute. Dr. Califano is an elected fellow of the American Association for the Advancement of Science (AAAS, 2015), the International Society for Computational Biology (ISCB, 2017) and Institute of Electrical and Electronics Engineers (IEEE, 1997). In 2018, he was elected to the National Academy of Medicine.

Departmental Appointments

  • Department of Systems Biology (Columbia University)
  • Department of Biochemistry and Molecular Biophysics
  • Department of Biomedical Informatics

Languages Spoken

  • French
  • Italian

Centers/Institutes/Programs

  • Herbert Irving Comprehensive Cancer Center

This provider does not accept new patients

Lab Locations

  • Irving Cancer Research Center

    1130 Street Nicholas Avenue
    Room 911/912
    New York, NY 10032
    Phone:
    (212) 851-5183

NIH Grants

  • QUANTUM COLLABORATION AWARD (Private)

    Aug 15 2018 - Dec 15 2023

    SYSTEMATIC IDENTIFICATION AND PHARMACOLOGICAL TARGETING OF TUMOR DEPENDENCIES FOR PRECISION CANCER MEDICINE (Federal Gov)

    Jul 1 2017 - Jul 31 2022

    ELUCIDATING THE DEPENDENCIES OF TUMOR INITIATING AND DRUG-RESISTANT NICHES IN HUMAN MALIGNANCIES BY GENOME-WIDE MOLECULAR PROFILING OF SINGLE CELLS (Federal Gov)

    Aug 14 2015 - Jul 31 2022

    THE CANCER DRUG COMBINATIONS INITIATIVE AT THE BROAD PHASE II (Private)

    Aug 1 2017 - Jul 31 2021

    CENTERS FOR CANCER SYSTEMS THERAPEUTICS (CAST) (Federal Gov)

    Aug 8 2016 - Jul 31 2021

    TARGETING MASTER REGULATOR DEPENDENCIES IN PEDIATRIC OSTEOSARCOMA (Private)

    Jul 1 2019 - Jun 30 2021

    CLINICAL TRANSLATION OF REGULATORY NETWORK-BASED PRECISION MEDICINE FOR PANCREATIC CANCER (Private)

    Apr 1 2018 - Mar 31 2021

    DEFINING THE ROLE OF ERG IN MODULATING THE AR CISTROME AND ANTIANDROGEN SENSITIVITY (Federal Gov)

    Apr 1 2015 - Mar 31 2020

    DEFINING THE ROLE OF ERG IN MODULATING THE AR CISTROME AND ANTIANDROGEN SENSITIVITY (Federal Gov)

    Apr 1 2015 - Mar 31 2020

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    ASSEMBLY OF CONTEXT-SPECIFIC GENE REGULATORY NETWORKS FOR THE SYSTEMATIC RECONSTRUCTION OF SINGLE-CELL STATES AND THEIRMOLECULAR DETERMINANTS (Private)

    Mar 1 2018 - Feb 28 2019

    GENE NETWORK PERTURBATIONS IN ALCOHOL DEPENDENCE - A SYSTEMS BIOLOGY APPROACH (Federal Gov)

    Sep 5 2013 - Aug 31 2018

    SYSTEMS BIOLOGY OF TUMOR PROGRESSION AND DRUG RESISTANCE (Federal Gov)

    Jun 1 2012 - Apr 30 2018

    GENE NETWORK PERTURBATIONS IN ALCOHOL DEPENDENCE - A SYSTEMS BIOLOGY APPROACH (Federal Gov)

    Sep 5 2013 - Aug 31 2017

    GENE NETWORK PERTURBATIONS IN ALCOHOL DEPENDENCE - A SYSTEMS BIOLOGY APPROACH (Federal Gov)

    Sep 5 2013 - Aug 31 2017

    STORAGE SYSTEM FOR HIGH PERFORMANCE COMPUTING (Federal Gov)

    Mar 15 2016 - Mar 14 2017

    EX VIVO COMPOUND PRIORITIZATION FOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (Private)

    Jul 1 2015 - Dec 31 2016

    ASSESSING SYNERGISTIC COMPOUND ACTIVITY IN GLIOBLASTOMA (Federal Gov)

    Sep 24 2015 - Oct 31 2016

    INVESTIGATION OF CYSVIEW CYTOTOXICITY FOR HUMAN BLADDER ORGANOIDS (Private)

    Aug 1 2015 - Jul 31 2016

    NATIONAL CENTER: MULTISCALE ANALYSIS OF GENOMIC AND CELLULAR NETWORKS (MAGNET) (Federal Gov)

    Sep 26 2005 - Jul 31 2016

    MERRIMACK PHARMACEUTICAL RNA-SEQ PROJECT (Private)

    Jul 21 2014 - Jul 20 2016

    CLINICAL AND TRANSLATIONAL SCIENCE AWARD (UL1) (Federal Gov)

    Sep 30 2006 - Jun 30 2016

    A SYSTEMS BIOLOGY APPROACH TO IDENTIFY AND EVALUATE NOVEL DRUG TARGET FOR AGGRESSIVE PROSTATE CANCER (Private)

    May 20 2013 - May 20 2016

    INTEGRATIVE ANALYSIS GENOMIC AND PROTEOMIC DATA FROM THE CANCER GENOME ATLAS (Federal Gov)

    Feb 1 2015 - Jan 31 2016

    COMPUTATIONAL ANALYSIS OF HIGH-GRADE GLIOMAS (Federal Gov)

    Sep 1 2009 - Aug 31 2015

    MOLECULAR PATHOGENESIS OF BASAL-LIKE BREAST CANCER (Federal Gov)

    Jul 1 2002 - Aug 31 2015

    ELUCIDATION OF CANCER PATHWAYS AND DRUGGABLE TARGETS USING MOUSE MODELS (Federal Gov)

    Sep 30 1999 - Jul 31 2015

    DISCOVERY OF AKT-REGULATED TRANSCRIPTIONAL MODULES ASSOCIATED WITH MALIGNANT PHENOTYPES IN BREAST CANCER (Federal Gov)

    Mar 1 2012 - Feb 28 2015

    DISSECTING THE MOLECULAR MECHANISM REGULATING SOMATIC CELL REPROGRAMMING (Private)

    Oct 1 2010 - Sep 30 2014

    GENE NETWORK PERTURBATIONS IN ALCOHOL DEPENDENCE - A SYSTEMS BIOLOGY APPROACH (Federal Gov)

    Sep 5 2013 - Aug 31 2014

    PROFILING SIGNATURES OF SYNERGISTIC CHEMICAL PERTURBATIONS IN DIVERSE CELLULAR C (Federal Gov)

    Sep 16 2011 - Aug 31 2014

    A SYSTEMS APPROACH TO ELUCIDATE MECHANISMS OF DRUG ACTIVITY AND SENSITIVITY USING LINCS DATA (Federal Gov)

    Sep 24 2011 - Jun 30 2014

    DATA COORDINATION CENTER FOR SERIOUS ADVERSE EVENT CONSORTIUM (Private)

    Jul 1 2010 - Mar 30 2014

    P2ALS INITIATIVE (Private)

    Jan 1 2011 - Dec 31 2013

    SAIC FREDERICK (Federal Gov)

    Sep 1 2012 - Sep 30 2013

    ELUCIDATING THE MECHANISMS OF NEUROENDOCRINE TUMOR INITIATION & PROGRESSION (Private)

    Oct 1 2011 - Sep 30 2013

    SUBPROJECT FOR INSTITUTION # 08-8993 (Private)

    Oct 1 2008 - Sep 30 2013

    HIGH-PERFORMANCE COMPUTE CLUSTER FOR BIOMEDICAL COMPUTING (Federal Gov)

    Aug 1 2012 - Jul 31 2013

    2009 CABIG IN SILICO RESEARCH CENTERS OF EXCELLENCE (Federal Gov)

    Sep 15 2009 - Sep 14 2012

    SYSTEMS BIOLOGY OF TUMOR PROGRESSION AND DRUG-RESISTANCE (Federal Gov)

    Sep 30 2009 - Aug 31 2012

    CABIG KNOWLEDGE CENTER FOR MOLECULAR ANALYSIS TOOLS (GEWORKBENCH, GENEPATTERN, CAINTEGRATOR) (Federal Gov)

    Jun 2 2008 - Jun 1 2012

    COLLABORATIVE STUDY ON THE SYSTEMS BIOLOGY OF VULNERABILITY TO STRESS (Federal Gov)

    Aug 1 2008 - May 31 2012

    IDENTIFICATION OF MASTER REGULATORS FOR STEM CELL PLURIPOTEN CY AND SELF-RENEWAL (Federal Gov)

    Apr 1 2010 - Mar 31 2012

    PATHWAY COMMONS: RESEARCH RESOURCE FOR BIOLOGICAL PATHWAYS (Federal Gov)

    Jan 4 2008 - Dec 31 2011

    INTEGRATION OF MOUSE MODELS INTO HUMAN CANCER RESEARCH (Federal Gov)

    Oct 5 2009 - Sep 30 2011

    INTEGRATION OF MOUSE MODELS INTO HUMAN CANCER RESEARCH (Federal Gov)

    Oct 5 2009 - Sep 30 2011

    GENETIC NETWORK INFERENCE WITH COMBINATIONAL PHENOTYPES (Federal Gov)

    Jun 21 2005 - Apr 30 2011

    INTEGRATIVE CANCER RESEARCH (ICR WORKSPACE DEVELOPER CABIG (Federal Gov)

    Mar 7 2008 - Apr 14 2011

    REGULATORY MODULES IN NORMAL AND TRANFORMED B-CELLS (Federal Gov)

    Jul 1 2005 - Mar 31 2011

    COMPUTATIONAL AND EXPERIMENTAL METHODS TO ELUCIDATE GENETIC REGULATORY MECHANISMS IN NORMAL AND MALIGNANT MAMMALIAN... (Private)

    Sep 1 2006 - Aug 31 2008

    ACADEMIC MEDICINE DEVELOPMENT COMPANY (Private)

    Dec 1 2001 - Jun 30 2005